



The apoA-I companY

Press Release

## ABIONYX Pharma announces its financial calendar for the year 2024

Toulouse, FRANCE, Lakeland, UNITED-STATES, March 7<sup>th</sup>, 2024, 7:00 pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar for 2024.

Events	Dates*
2023 Full-Year Results	Monday, March 11, 2024
Cash position and activity update for Q1 2024	Thursday, May 16, 2024
Cash position and activity update for Q2 2024	Thursday, August 22, 2024
2024 Half-Year Results	Thursday, September 26, 2024
Cash position and activity update for Q3 2024	Thursday, November 14, 2024

*\* indicative dates subject to change*

### About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.

### Contacts:

#### NewCap

Investor relations  
Nicolas Fossiez  
Louis-Victor Delouvrier  
abionyx@newcap.eu  
+33 (0)1 44 71 98 53

#### NewCap

Media relations  
Arthur Rouillé  
abionyx@newcap.eu  
+33 (0)1 44 71 00 15